These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
146 related items for PubMed ID: 4834974
1. Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Markham C, Diamond SG, Treciokas LJ. Arch Neurol; 1974 Aug; 31(2):128-33. PubMed ID: 4834974 [No Abstract] [Full Text] [Related]
5. [Long term treatment of a parkinsonism with l-dopa]. Presthus J. Tidsskr Nor Laegeforen; 1973 Oct 10; 93(28):2111-3. PubMed ID: 4590069 [No Abstract] [Full Text] [Related]
6. The effects of combining carbidopa with levodopa for Parkinson's disease. Martin WE, Tolosa ES, Loewenson RB, Lee MC, Resch JA, Baker AB. Geriatrics; 1975 Dec 10; 30(12):39-44. PubMed ID: 1104406 [No Abstract] [Full Text] [Related]
7. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease. Andrews CJ, Somerville B. Med J Aust; 1974 Mar 23; 1(12):429-32. PubMed ID: 4598384 [No Abstract] [Full Text] [Related]
8. L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease. Glasgow GL, Henley JW, Willoughby EW. Aust N Z J Med; 1974 Aug 23; 4(4):373-8. PubMed ID: 4278910 [No Abstract] [Full Text] [Related]
9. Levodopa in treating Parkinsonism. O'Doherty DS. Am Fam Physician; 1971 Nov 23; 4(5):95-9. PubMed ID: 5117507 [No Abstract] [Full Text] [Related]
10. A double-blind controlled study of MK-486 in Parkinson's disease. Schwartz AM, Olanow CW, Spencer A. Trans Am Neurol Assoc; 1973 Nov 23; 98():301-3. PubMed ID: 4594189 [No Abstract] [Full Text] [Related]
12. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Marsden CD, Parkes JD, Rees JE. Lancet; 1973 Dec 29; 2(7844):1459-62. PubMed ID: 4129310 [No Abstract] [Full Text] [Related]
13. [Results of the treatment of Parkinson's diseases with carbidopa and L-Dopa]. Cáceres AF. Rev Fac Cienc Med Cordoba; 1974 Dec 29; 32(2):161-74. PubMed ID: 4619691 [No Abstract] [Full Text] [Related]
14. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Fahn S. Neurology; 1974 May 29; 24(5):431-41. PubMed ID: 4857104 [No Abstract] [Full Text] [Related]
15. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study]. Wälzholz U, Schönfelder H. Nervenarzt; 1972 Oct 29; 43(10):531-2. PubMed ID: 4628192 [No Abstract] [Full Text] [Related]
16. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease. Lieberman A, Goodgold A, Jonas S, Leibowitz M. Neurology; 1975 Oct 29; 25(10):911-6. PubMed ID: 1101099 [Abstract] [Full Text] [Related]
17. Combined treatment of parkinsonism with L-dopa and amantadine. Godwin-Austen RB, Frears CC, Bergmann S, Parkes JD, Knill-Jones RP. Lancet; 1970 Aug 22; 2(7669):383-5. PubMed ID: 4194690 [No Abstract] [Full Text] [Related]
18. [L-tryptophan therapy of DOPA psychoses]. Birkmayer W, Neumayer E. Nervenarzt; 1972 Feb 22; 43(2):76-8. PubMed ID: 4501978 [No Abstract] [Full Text] [Related]
19. Levodopa with benserazide or carbidopa in Parkinson disease. Rinne UK, Mölsä P. Neurology; 1979 Dec 22; 29(12):1584-9. PubMed ID: 574221 [Abstract] [Full Text] [Related]